Graham Partners’ Latest Platform Is Just What the Doctor Ordered
July 28th, 2014
PHILADELPHIA, July 28, 2014 – Graham Partners, a private investment firm focused on investing in businesses with advanced manufacturing technologies, innovative product development capabilities, and strong growth potential, is pleased to announce its acquisition of HemaSource Holdings, LLC (“HemaSource”). HemaSource, headquartered in West Jordan, Utah, is a leading supplier of medical disposables to blood therapies companies and is also a leader in medical product distribution to plasma collection centers.
Graham Partners’ sourcing efforts continue to bear fruit – the HemaSource acquisition is the most recent transaction that closed as a result of the firm’s targeted investment theme program. At the end of 2008, Graham Partners identified the medical products industry as a targeted area of interest due to the large number of U.S. medical products companies and steady long-term growth rates within the industry. HemaSource fell squarely in line with a sector of interest, disposable medical products, and met the majority of the firm’s internally developed, medical products specific screening criteria. Further enhancing its position as the preferred buyer, Graham Partners was able to expedite its due diligence as a result of its dedicated operating resources with industry-specific experience and contacts, and convince HemaSource’s management of Graham Partners’ ability to deliver value-added resources to the company post-transaction.
HemaSource is positioned for growth under Graham’s ownership as a result of increased global demand for plasma-derived products, a recurring revenue stream, and longstanding customer relationships. Additionally, the plasma and plasma-based products industry, which HemaSource serves, is $17 billion in size and has grown 8% per annum over the last four years*. In addition to its own proprietary products, the company’s access to more than 1,300 SKUs from leading medical products manufacturers yields a broad selection of innovative products that enable HemaSource to deliver a complete offering to its customers. The company’s value-added MRP services and its reputation within the industry for superior customer service further serve as competitive advantages.
Todd Tracey, CEO of HemaSource, states, “The knowledge and resources Graham Partners brought to the table during the transaction process convinced us they are the right fit as a partner to support HemaSource’s future growth potential.”
Josh Wilson, Managing Principal at Graham Partners adds, “Graham was attracted to HemaSource’s underlying growth potential driven by an increasing demand for plasma protein therapeutics. HemaSource has achieved high customer satisfaction due to its compelling software offering and its ongoing effort to co-develop niche products with its largest customers. We look forward to partnering with the company’s strong management team and deploying our operational resources in order to accelerate growth and further drive best practices across all functional areas of the company.”
*Health Advances, LLC. Final Report: Project Utes. Boston: 2014.
FOR FURTHER INFORMATION CONTACT: